CaboPoint, a phase II, open-label study of cabozantinib as second-line therapy for patients with clear cell metastatic renal cell carcinoma (RCC), whose disease progressed after therapy with checkpoint inhibitors (CPIs)

被引：0
|
作者：
Albiges, Laurence
Schmidinger, Manuela
Pioger, Naila Taguieva
Perol, David
Gruenwald, Viktor
机构：
[1] Univ Paris Saclay, Med Oncol, Villejuif, France
[2] Med Univ Vienna, Vienna, Austria
[3] Ipsen Pharma, Boulogne, France
[4] Ctr Leon Berard, Dept Clin Res, Lyon, France
[5] Hannover Med Sch, Dept Hematol Hemostaseol Oncol & Stem Cell Transp, Hannover, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS772
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial
    Hutson, Thomas E.
    Lesovoy, Vladimir
    Al-Shukri, Salman
    Stus, Viktor P.
    Lipatov, Oleg N.
    Bair, Angel H.
    Rosbrook, Brad
    Chen, Connie
    Kim, Sinil
    Vogelzang, Nicholas J.
    LANCET ONCOLOGY, 2013, 14 (13): : 1287 - 1294
  • [42] An open-label phase II study of first- and second-line treatment with brivanib in patients with hepatocellular carcinoma (HCC)
    Raoul, J. L.
    Finn, R. S.
    Kang, Y. K.
    Park, J. W.
    Harris, R.
    Coric, V.
    Donica, M.
    Walters, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [43] A Single-arm, Multicenter, Open-label Phase 2 Study of Lapatinib as the Second-line Treatment of Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma
    Wuelfing, Christian
    Machiels, Jean-Pascal H.
    Richel, Dirk J.
    Grimm, Marc-Oliver
    Treiber, Uwe
    De Groot, Marco R.
    Beuzeboc, Philippe
    Parikh, Roma
    Petavy, Frank
    El-Hariry, Iman A.
    CANCER, 2009, 115 (13) : 2881 - 2890
  • [44] Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study
    Huang, Jing
    Xu, Jianming
    Chen, Yun
    Zhuang, Wu
    Zhang, Yiping
    Chen, Zhendong
    Chen, Jia
    Zhang, Helong
    Niu, Zuoxing
    Fan, Qingxia
    Lin, Lizhu
    Gu, Kangsheng
    Liu, Ying
    Ba, Yi
    Miao, Zhanhui
    Jiang, Xiaodong
    Zeng, Ming
    Chen, Jianhua
    Fu, Zhichao
    Gan, Lu
    Wang, Jun
    Zhan, Xianbao
    Liu, Tianshu
    Li, Zhiping
    Shen, Lin
    Shu, Yongqian
    Zhang, Tao
    Yang, Qing
    Zou, Jianjun
    LANCET ONCOLOGY, 2020, 21 (06): : 832 - 842
  • [45] A single-arm, multicenter, open-label phase II trial of cabazitaxel as second-line treatment for patients with locally advanced or metastatic transitional cell carcinoma (TCC)
    Peer, Avivit
    Neumann, Avivit
    Keizrnan, Daniel
    Frank, Stephen Jay
    Berger, Raanan
    Leitzin, Larisa
    Pinto, Ester
    Neiman, Victoria
    Rosenbaum, Eli
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [46] A multicentric, single arm, open-label, phase I/II study evaluating PSMA targeted radionuclide therapy in adult patients with metastatic clear cell renal cancer (PRadR)
    Kryza, David
    Vinceneux, Armelle
    Bidaux, Anne-Sophie
    Garin, Gwenaelle
    Tatu, Delphine
    Cropet, Claire
    Badel, Jean-Noel
    Perol, David
    Giraudet, Anne-Laure
    BMC CANCER, 2024, 24 (01)
  • [47] Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4)
    Motzer, R. J.
    Alyasova, A.
    Ye, D.
    Karpenko, A.
    Li, H.
    Alekseev, B.
    Xie, L.
    Kurteva, G.
    Kowalyszyn, R.
    Karyakin, O.
    Neron, Y.
    Cosgriff, T.
    Collins, L.
    Brechenmacher, T.
    Lin, C.
    Morgan, L.
    Yang, L.
    ANNALS OF ONCOLOGY, 2016, 27 (03) : 441 - 448
  • [48] A single-arm, multicenter, open-label phase II trial of cabazitaxel as second-line treatment for patients with locally advanced or metastatic transitional cell carcinoma (TCC).
    Peer, Avivit
    Neumann, Avivit
    Keizman, Daniel
    Frank, Stephen Jay
    Berger, Raanan
    Leitzin, Larisa
    Pinto, Ester
    Neiman, Victoria
    Rosenbaum, Eli
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [49] A multicentric, single arm, open-label, phase I/II study evaluating PSMA targeted radionuclide therapy in adult patients with metastatic clear cell renal cancer (PRadR)
    David Kryza
    Armelle Vinceneux
    Anne-Sophie Bidaux
    Gwenaelle Garin
    Delphine Tatu
    Claire Cropet
    Jean-Noël Badel
    David Perol
    Anne-Laure Giraudet
    BMC Cancer, 24
  • [50] An Open-Label Phase II Trial of Pembrolizumab, an Immune Checkpoint Inhibitor Alone or in Combination With Oral Azacitidine as Second-Line Therapy for Advanced Head and Neck Squamous Cell Cancers
    Ramani, Vinod K.
    Gayen, Srimonta
    Naik, Radheshyam
    HEALTH SCIENCE REPORTS, 2025, 8 (01)
12345